Lexaria Bioscience News

Lexaria Bioscience Begins Dosing In GLP-1 Animal Study

Lexaria Bioscience Begins Dosing In GLP-1 Animal Study

BenzingaMay 17 21:12

Here's Why We're Watching Lexaria Bioscience's (NASDAQ:LEXX) Cash Burn Situation

Yahoo FinanceMay 9 22:25

Lexaria Begins Dosing of Its Second GLP-1 Human Pilot Study

Stockhouse May 8 21:10

Lexaria Announces New Research Program to Evaluate Mode of Action and Performance of DehydraTECH-GLP-1 Drugs

KELOWNA, BC / ACCESSWIRE / May 6, 2024 / Lexaria Bioscience Corp. , a global innovator in drug delivery platforms announces an applied research

AccesswireMay 6 21:05

Lexaria to Receive $4.7 Million Gross Proceeds in Warrant Exercise and Issuance

KELOWNA, BC / ACCESSWIRE / April 30, 2024 / Lexaria Bioscience Corp. , a global innovator in drug delivery platforms announces it has entered

AccesswireMay 1 03:40

Lexaria Bioscience, Biosig Technologies, BIMI Holdings Among Healthcare Movers

Seeking AlphaApr 17 22:00

12 Health Care Stocks Moving In Tuesday's After-Market Session

GainersClene (NASDAQ:CLNN) shares moved upwards by 54.9% to $0.48 during Tuesday's after-market session. The company's market cap stands at $61.6 million. Talphera (NASDAQ:TLPH) shares moved upwards b

BenzingaApr 17 04:31

Lexaria Receives Ethics Review Board Approval to Begin New GLP-1 Study

Human Pilot Study #2 Approved KELOWNA, BC / ACCESSWIRE / April 16, 2024 / Lexaria Bioscience Corp. , a global innovator in drug

AccesswireApr 16 21:10

Lexaria Bioscience (LEXX.US): The 2024 Q2 financial report achieved revenue of US$145,000, with a previous value of US$350.2 million; earnings per share of -0.06 dollars, previous value of -0.22 dollars, and expected value of -0.10 dollars.

Lexaria Bioscience (LEXX.US): The 2024 Q2 financial report achieved revenue of US$145,000, with a previous value of US$350.2 million; earnings per share of -0.06 dollars, previous value of -0.22 dollars, and expected value of -0.10 dollars.

Zhitong FinanceApr 10 05:50

Lexaria Awarded New Patents

Lexaria receives new patents in the fields of epilepsy and anti-viral agentsKELOWNA, BC / ACCESSWIRE / April 2, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria")

AccesswireApr 2 21:00

Lexaria Bioscience Showcases Drug Delivery Breakthrough

TipRanksMar 22 01:07

Lexaria to Present at The LD Micro Invitational XIV

Yahoo FinanceMar 21 21:20

Lexaria Bioscience Welcomes New CFO

TipRanksMar 15 00:37

Lexaria Appoints Nelson Cabatuan As Chief Financial Officer, Effective Immediately

Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces the appointment of Nelson Cabatuan, CPA, as Chief Financial O

BenzingaMar 14 21:22

Lexaria Bioscience Files to Sell 1.61M Shares of Common Stock for Holders

Seeking AlphaMar 13 05:20

12 Health Care Stocks Moving In Tuesday's Intraday Session

GainersRegulus Therapeutics (NASDAQ:RGLS) stock increased by 94.9% to $2.69 during Tuesday's regular session. The company's market cap stands at $54.3 million. Bright Green (NASDAQ:BGXX) shares increa

BenzingaMar 13 01:31

FGEN, LEXX and SGLY Among Mid-day Movers

Seeking AlphaMar 13 00:21

Lexaria Bioscience Advances Oral Diabetes Treatment

TipRanksMar 8 02:37

Lexaria Bioscience Hires Contract Research Organization To Perform Co.'s Next GLP-1 Human Pilot Study

Lexaria Bioscience Hires Contract Research Organization To Perform Co.'s Next GLP-1 Human Pilot Study

BenzingaMar 7 22:08

Sector Update: Health Care Stocks Retreating Late Afternoon

Health care stocks fell late Tuesday afternoon, with the NYSE Health Care Index and the Health Care Select Sector SPDR Fund (XLV) each dropping about 1%. The iShares Biotechnology ETF (IBB) slumped 1.

MT NewswiresMar 6 04:59